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Abstract We investigated the role of neurofilament (NF)
proteins in Alzheimer disease (AD) neurofibrillary degeneration.
The levels and degree of phosphorylation of NF proteins in AD
neocortex were determined by Western blots developed with a
panel of phosphorylation-dependent NF antibodies. Levels of all
three NF subunits and the degree of phosphorylation of NF-H
and NF-M were significantly increased in AD as compared to
Huntington disease brains used as control tissue. The increase in
the levels of NF-H and NF-M was 1.7- and 1.5-fold (P6 0.01) as
determined by monoclonal antibody SMI33, and was 1.6-fold
(P6 0.01) in NF-L using antibody NR4. The phosphorylation of
NF-H and NF-M in AD was increased respectively at the SMI31
epitope by 1.6- and 1.9-fold (P6 0.05) and at the SMI33 epitope
by 2.7- and 1.3-fold (P6 0.01 and P6 0.05). Essentially similar
effects were observed in SY5Y human neuroblastoma cells when
treated with okadaic acid, an inhibitor of protein phosphatase
(PP)-2A and -1. This is the first biochemical evidence which
unambiguously demonstrates the hyperphosphorylation and the
accumulation of NF subunits in AD brain, and shows that the
inhibition of PP-2A/PP-1 activities can lead to the hyperphos-
phorylation of NF-H and NF-M subunits. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
The neuro¢lament (NF) is the intermediate ¢lament of the
neuron. NF is composed of three protein subunits with ap-
parent molecular masses of V200 kDa (NF-H), 140^160 kDa
(NF-M), and 68^70 kDa (NF-L) [1,2]. The highly repetitive
Lys-Ser-Pro (KSP) motif present in the tail domain/C-termi-
nal region of NF-H and NF-M is highly phosphorylated in
vivo [3^5]. The phosphorylated NFs appear to be localized
mainly in the axon, whereas the dephosphorylated forms are
found in the cell body and dendrites [6^8], suggesting the
importance of NF phosphorylation in its transport and inter-
action with other cytoskeletal proteins.
In Alzheimer disease (AD) brain the neuro¢brillary degen-
eration, a hallmark of the disease, is believed to be the result
of a protein phosphorylation/dephosphorylation imbalance
[9^11]. The activities of protein phosphatase (PP)-2A/PP-1
which regulate the phosphorylation of tau [12^14], the major
protein subunit of paired helical ¢laments (PHF)/neuro¢bril-
lary tangles [15], are compromised in AD brain [16,17] and
probably contribute to the protein phosphorylation/dephos-
phorylation imbalance. Thus, one or more neuronal proteins
other than tau might also become hyperphosphorylated in the
a¡ected areas of AD brain. Immunocytochemically phosphor-
ylated NF-H and NF-M subunits were reported in tangle-
bearing neurons in AD brain previously [18]. However, the
cross-reaction of NF antibodies with abnormally phosphory-
lated tau made these results uncertain [19^21]. In the present
study, we resolved this question by using Western blots to
distinguish NF proteins (NFPs) and tau by their di¡erent
apparent molecular weights and show that in AD neocortex
as compared with Huntington disease (HD) brain used as a
control, the levels of all three neuro¢lament subunits are in-
creased and that at least NF-H and NF-M are signi¢cantly
hyperphosphorylated at several sites. The present study also
shows that the treatment of human neuroblastoma SY5Y cells
with okadaic acid (OA), an inhibitor of PP-2A and -1, also
results in the phosphorylation and accumulation of NF-H and
NF-M subunits as seen in AD.
2. Materials and methods
2.1. Brain samples and antibodies
For this study neocortex from 20 AD (76 þ 5.8 years) and as con-
trols 20 HD (69 þ 12 years) cases was employed. The brains had been
removed 3^6 h post mortem and were stored frozen at 375‡C until
used. All AD cases had histopathologically con¢rmed diagnosis. HD
diagnosis was based on both family history and neuropathological
examination. Autopsied brain specimens were obtained from the
Brain Tissue Resource Center (Public Health Service Grant MH/NS
31862), McLean Hospital, Belmont, MA, USA, and from the IBR
Brain Bank (Dr. Piotr Kozlowski). The source, speci¢city, and the
dilution of the antibodies used are described in Table 1.
2.2. Immunocytochemistry
Neighboring sections of formalin-¢xed, para⁄n-embedded Alz-
heimer hippocampus (6 Wm) were immunostained with monoclonal
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antibody (mAb) Tau-1 (ascites, 1:50 000) after dephosphorylation of
the tissue [9] or with antibody SMI34 (Sternberger Monoclonals, Lu-
therville, MD, USA; 1:20 000) and developed using the Vector Elite
Kit (Vector Laboratories, Burlingame, CA, USA). SY5Y cells were
¢xed for 10 min in 4% paraformaldehyde in 1Uphosphate-bu¡ered
saline (PBS) prewarmed at 37‡C, washed three times in PBS contain-
ing 0.1% Triton X-100 and incubated with PBS containing 10% goat
serum, 3% bovine serum albumin, and 2% Tween-20 for 1 h at room
temperature to block non-speci¢c binding of antibodies. Primary anti-
bodies were added at the dilutions shown in Table 1 and incubated at
4‡C overnight. Bound antibodies were detected by using the Histo-
stain SP kit from Zymed (Beijing, PR China) with diaminobenzidine
as a substrate. Levels of antibody bound to cells were analyzed by
Kodak Image System IPP Analysis Software (Cold Spring Harbor
Inc., Beijing, PR China). At least 500 cells per experiment were ana-
lyzed. For statistical analysis of the data Student’s t-test was used.
Each experiment was carried out at least three times.
2.3. Tissue fractionation and quantitative Western blot analysis
Cerebral gray matter was cleaned free of any underlying white
matter, washed in ice-cold bu¡er containing 50 mM HEPES, pH
6.8, 1 mM EGTA, and 1% L-mercaptoethanol (BME), and blood
clots and meninges were removed. The tissue was then homogenized
in the above bu¡er (1:0.75 w/v) containing 0.5 mM phenylmethylsul-
fonyl £uoride (PMSF), 50 mM NaF, and 10 Wg/ml each of leupeptin,
pepstatin A and aprotinin. The homogenate was centrifuged at
75 000Ug for 1 h and separated into a supernatant and a pellet.
The pellet was rehomogenized and dissolved by heating for 5 min in
Laemmli sample bu¡er, containing 60 mM Tris^HCl, pH 6.8, 3%
sodium dodecylsulfate, 5% BME, 10% glycerol and 0.05% bromophe-
nol blue. Protein concentrations were measured by the modi¢ed
Lowry method [22].
Proteins were separated by SDS^PAGE. The amount of protein
loaded per gel lane was as follows: 16 Wg/lane for SMI31, 24 Wg for
SMI34, 8 Wg for SMI33 and 32 Wg for SMI32 and for NR4. After
transfer of proteins to polyvinylidene di£uoride membranes (Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA), blots were probed
with primary mAbs SMI31, SMI32, SMI33, SMI34 or NR4 (Table 1)
and developed with 125I-labeled antibodies to mouse IgG (0.5 Wg/ml,
Amersham Pharmacia) as secondary antibodies. Images were pro-
cessed with the aid of a computerized Fuji 1500 Imaging System
and expressed as PSL [23]. Student’s t-test was used for statistical
analysis. Dephosphorylation, where required, was carried out on the
blot with bovine calf intestine alkaline phosphatase (Sigma, St. Louis,
MO, USA) as previously described [9]. For each case the values ob-
tained with the phosphorylation-dependent antibodies were normal-
ized against the corresponding immunoreactivities obtained with mAb
SMI33 after dephosphorylation (total NF-H and NF-M). The percent
phosphorylation at the SMI33 and SMI32 epitopes was calculated
from the immunoreactivities (IR) obtained before and after dephos-
phorylation by using the following formula: (IR total3IR not de-
phos)U100/IR total. IR total = immunoreactivity after dephosphory-
lation.
2.4. Cell culture and treatment with okadaic acid
SH-SY5Y cells were obtained from Dr. J.L. Biedler (Sloan Ketter-
ing Institute, New York, NY, USA) and were propagated in Dulbec-
co’s modi¢ed Eagle’s medium (Gibco BRL, Beijing, PR China) with
5% fetal bovine serum and penicillin/streptomycin (5% CO2 and 95%
air). Cells were plated at a density of 1.0U105 cells/cm2 on glass
coverslips for immunocytochemistry or at a density of 5U106 cells/
35 mm dish for immunoblotting. For OA treatment, cells were cul-
tured in the presence of 0, 15 or 30 nM of the drug for 24 h, and then
either washed, lysed in sample bu¡er containing phosphatase and
protease inhibitors and employed for Western blots, or ¢xed in 4%
paraformaldehyde and used for immunocytochemical staining with
antibodies SMI31, SMI32, SMI33 or SMI34.
3. Results
3.1. Subcellular distribution of NFPs in AD brain
The distribution of phosphorylated NFPs in AD brain was
examined immunocytochemically by staining sections of hip-
pocampus with mAb SMI34 at a 1:20 000 dilution. On West-
ern blots at this dilution the antibody only reacted with NF-
H/-M but not with Alzheimer hyperphosphorylated tau,
whereas in AD hippocampus tissue sections it strongly labeled
a number of tangles and neuropil threads. However, consid-
erably fewer structures were labeled by the neuro¢lament anti-
body when compared to immunolabeling of the alkaline phos-
phatase-treated sections with mAb Tau-1 (Fig. 1).
The distribution of NFPs between the 75 000Ug pellet and
supernatant of AD brain homogenate was studied by Western
blots (Fig. 2). In the particulate fraction all antibodies tested
strongly labeled protein bands with apparent molecular mass
V200 kDa, 160^150 kDa or 68 kDa corresponding to NF-H,
NF-M and NF-L, respectively. Antibodies SMI31 and SMI33
detected both NF-H and NF-M, whereas SMI34 detected
only NF-H and SMI32 detected preferentially NF-M. In the
same fraction antibody NR4 to NF-L labeled a protein of a
molecular mass of 68 kDa. In contrast, in the supernatant
fraction, a 6 150 kDa doublet and a V230 kDa protein
were detected by antibody SMI33. When the blot was over-
exposed the same proteins were also labeled by SMI31 (data
not shown). Preliminary data indicate that these proteins were
not NFPs but spectrins (Wang et al., manuscript in prepara-
tion). These ¢ndings show that, in contrast to fresh animal
brain where NFPs were observed both in supernatant and in
pellet fractions [24,25], in human autopsy tissue the neuro¢la-
ment polypeptides separate in the pellet fraction.
3.2. Protein levels and degree of phosphorylation of NFPs in
AD and HD brains
Since NFPs were only detected in the particulate brain
fractions, we studied the total protein levels and the phos-
phorylation states of NFPs in this fraction from AD and as
neurological control age-matched HD cases (Fig. 3). Total
NF-H and NF-M levels were determined by quantitative
Western blots using antibodies SMI32 and SMI33. We found
that antibodies SMI33 and SMI32 reacted maximally with
NF-H and NF-M, respectively, after treatment of the blots
with alkaline phosphatase prior to antibody application. The
blots showed that the total immunoreactivity levels of NF-H
Table 1
Antibodies employed
Antibody Type Dilution Speci¢city Source
SMI31 Pa 1:5000 NF-H, NF-M Sternberger Mono Inc.
SMI32 NPb 1:5000 NF-H, NF-M Sternberger Monoclonals Inc.
SMI33 NP 1:5000 NF-H, NF-M Sternberger Monoclonals Inc.
SMI34 P 1:5000 NF-H Sternberger Monoclonals Inc.
NR4 1:500 NF-L Dako
Tau-1 NP 1:50000 Tau Ser 195/198/199/202 [9,44]
a;bReactive with neuro¢lament proteins H and M only if they are aphosphorylated or bnot phosphorylated at speci¢c site(s).
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and NF-M determined by SMI33 after dephosphorylation
were respectively 1.7-fold (P6 0.01) and 1.5-fold (P6 0.01)
higher in AD than in HD brains (n = 20 each), whereas with-
out dephosphorylation no signi¢cant di¡erence was detected
in the NFP levels between AD and controls (Fig. 3A,B). Sim-
ilarly, with mAb SMI32 after dephosphorylation the levels of
NF-M were 1.6-fold (Ps 0.05; n = 11 each) higher in AD
than in HD brains (Fig. 3A,B). The levels of NF-H could
not be determined in AD brain with this antibody since
even after extensive dephosphorylation this band was not la-
beled in most of the samples studied (n = 11). This was prob-
ably due to the blockage of the SMI32 epitope by a posttrans-
lational modi¢cation other than phosphorylation in AD. As
in the case of NF-H and NF-M a 1.6-fold (P6 0.01; n = 7
each) increase in the NF-L levels in AD as compared to HD
brains was detected by mAb NR4 (Fig. 3A,B).
The degree of phosphorylation at the SMI33 epitope was
deduced from the immunoreactivity levels calculated for NF-
H and NF-M before and after dephosphorylation (Fig. 3C).
Despite high individual variations, we found that both NF-H
and NF-M were generally phosphorylated to a higher degree
in AD than in HD brains. In NF-H V40% of the SMI33
epitope was phosphorylated in AD versus V15% in HD
brains (P6 0.001; n = 20 each). For NF-M the degree of
phosphorylation was V43% in AD and V32% in HD but
the di¡erence was not statistically signi¢cant (Fig. 3C). The
degree of phosphorylation at the SMI32 epitope was not de-
termined because in most of the samples no staining was
detected without prior dephosphorylation (Fig. 3A). The de-
gree of phosphorylation at the SMI31 epitope was 1.9-fold
(P6 0.05; n = 11 each) higher in both NF-H and NF-M in
AD than in HD brains, and at the SMI34 epitope of NF-H it
was 1.4-fold (P6 0.05; n = 11 each) increased in AD (Fig.
3D). Because of the increased levels of the NFPs in AD, phos-
phorylation at the SMI31 and SMI34 epitopes was further
calculated by normalizing the values obtained with these anti-
bodies in the individual samples against the respective total
levels of NF subunits determined with SMI33 after dephos-
phorylation (Fig. 3E). Under these conditions we found that
the degree of phosphorylation at the SMI31 epitope was 1.6-
fold (P6 0.05) and 1.9-fold (P6 0.05) respectively higher in
the NF-H and NF-M subunits of AD as compared to the HD
controls. However, no signi¢cant di¡erence in phosphoryla-
tion between AD and HD was detected with SMI34 after
normalization.
3.3. Dose-dependent induction of hyperphosphorylation and
accumulation of NF-H/-M in SY5Y neuroblastoma cells
by treatment with OA
To investigate the possibility that the abnormal hyperphos-
phorylation and elevation of NFPs observed in AD brain
might be caused by a decrease in the activities of protein
phosphatases, we induced an AD-like decrease in PP-2A/
PP-1 activities by treating SY5Y cells with 15 or 30 nM OA.
Fig. 2. Distribution of NFPs in supernatant (lanes 1^4) and particu-
late fractions (lanes 5^8) of the neocortex from four AD cases.
Western blots of NF-H and NF-M immunostained with antibodies
(a) SMI31; (b) SMI34; (c) SMI32, after treatment of the blot with
alkaline phosphatase (+AP); (d) SMI33; (e) Western blot of NF-L
with NR4. The position of V230 kDa and 6 150 kDa mass pro-
teins on the blot in panel d is marked by arrow heads.
Fig. 1. Immunohistochemical staining of neighboring sections of an AD hippocampus with (a) phosphorylation-dependent neuro¢lament anti-
body SMI34 (1:20 000) and (b) an alkaline phosphatase-treated section with Tau-1 (1:50 000). SMI34 at 1:20 000 dilution does not cross-react
with hyperphosphorylated tau on Western blots.
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FEBS 25339 11-10-01
J.-z. Wang et al./FEBS Letters 507 (2001) 81^8784
Previously, we have shown that the treatment of SY5Y cells
with 10 nM OA for 24 h inhibits almost 100% of PP-2A and
V75% of PP-1 activities [23]. Since tau in OA-treated SY5Y
cells is hyperphosphorylated at several sites [23] we ¢rst
studied the degree of its cross-reactivity with the phosphory-
lation-dependent antibodies SMI31 and SMI33 to NF on
Western blots. We found negligible immunoreactivity with
the phosphorylated tau in OA-treated cells (data not shown)
Fig. 3. 125I Western blot pro¢les and levels of NFPs in the particulate fraction of AD and HD brains. A: Western blots were developed with
antibodies to non-phosphorylated (SMI33, SMI32) and phosphorylated (SMI31, SMI34) epitopes on NF-H and NF-M (AD, lanes 1^7; HD,
lanes 8^14) and the NF-L (NR4) subunits (AD odd and HD even numbers). (3AP) and (+AP) indicates whether the blots had been treated
with alkaline phosphatase prior to application of the antibodies to unmask the SMI33 and SMI32 epitopes. B^E: Bar graphs represent
means þ S.D. of (B) the relative levels of total 125I immunoreactivities (IR) from scans of Western blots that were developed with SMI33 (n = 20
AD and HD cases each) or SMI32 (n = 11 each) for NF-H and NF-M without or with prior treatment of the blot with alkaline phosphatase
(+AP; 3AP) and with NR4 for NF-L (n = 7 each); (C) the percentage of phosphorylation at the SMI33 epitope; (D) the degree of phosphory-
lation at the SMI31 and SMI34 (n = 11 each) epitopes of NF-H and NF-M subunits; (E) the degree of phosphorylation at the SMI31 and
SMI34 epitopes after normalization against the total NF-H or NF-M levels (SMI33 after dephosphorylation). For SMI33 the percentage of
phosphorylation was calculated from the IR obtained in B as {(SMI33(+AP)3SMI33(3AP))/SMI33(+AP)}U100 where IR SMI33(+AP) is as-
sumed to represent the total IR. Phosphorylation at the SMI31 and SMI34 epitopes in AD and HD cases is expressed in IR that had been
normalized in pair against the total NF subunit levels (IR SMI33+AP). *P6 0.05, **P6 0.01.
6
Fig. 4. Hyperphosphorylation of NFP in OA-treated SY5Y cells. A: SY5Y cells were treated with 0, 15 or 30 nM OA and immunocytochemi-
cally stained with NF antibodies. Representative micrographs of cells that were treated without OA (a,d,g,j); 15 nM OA (b,e,h,k); and 20 nM
OA (c,f,i,l) for 24 h, and immunostained with SMI33 (a^c); SMI32 (d^f); SMI31 (g^i) and SMI34 (j^l). B: Bar graphs represent the intensity
(in arbitrary units) of immunostaining per cell. The values are the averages obtained from at least 500 cells and three separate experiments.
***P6 0.001.
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indicating the NF speci¢city of the immunocytochemical re-
action. Antibodies SMI33 (Fig. 4A, a^c) and SMI32 (Fig. 4A,
d^f) to non-phosphorylated epitopes of NF-H and NF-M
stained most strongly the untreated SY5Y cells. The immuno-
label was mostly in the cell bodies and to a lesser degree in the
processes. In the OA-treated cells the staining dramatically
decreased and was mostly concentrated around the nuclei
and in the proximal ends of the processes. The reverse picture
was observed with SMI31 (Fig. 4A, g^i) and SMI34 (Fig. 4A,
j^l) to phosphorylated NFP epitopes; namely, only weak la-
beling of cell bodies and processes of the untreated cells and
increased staining densities of the cells exposed to OA. Very
similar results were obtained with image analysis of the im-
munolabeled cells, i.e. decreased levels of labeling of the OA-
treated cells with the antibodies to dephosphorylated NFPs
and increased levels of staining with the antibodies recogniz-
ing phosphorylated NFPs (Fig. 4B).
4. Discussion
Based on immunocytochemical studies at light and electron
microscopic level with polyclonal and monoclonal antibodies
to neuro¢laments it had been believed for a number of years
that the Alzheimer neuro¢brillary tangles, the hallmark lesion
of this disease, were composed of NF [18,26^29]. However,
subsequently it was shown that some of these antibodies im-
munologically cross-reacted with abnormally hyperphos-
phorylated tau [19^21] which is the major protein subunit of
paired helical ¢laments/neuro¢brillary tangles [9,15]. Whether
and to what extent neuro¢lament proteins are actually hyper-
phosphorylated in the AD brain has remained an enigma. In
the present study we demonstrate that NFPs are indeed accu-
mulated in hyperphosphorylated form in the AD brain. Fur-
thermore, we show that the treatment of SY5Y cells in culture
with OA, a PP-2A/PP-1 inhibitor, induces the accumulation of
phosphorylated NFPs in the cell bodies.
In the normal neuron all three axonal NFPs are phosphor-
ylated. However, there are di¡erences in degree of phosphor-
ylation between the subunits. Unlike NF-H and NF-M in
which the numbers of phosphorylation sites are very large
and which are mainly located in the C-terminal long tail re-
gion, NF-L is less phosphorylated and the phosphorylation
sites are in the N-terminus of the protein [30]. NFPs in highly
phosphorylated form are normally major components of the
axonal cytoskeleton. They are synthesized and assembled for
axonal transport in the cell body and their phosphorylation
occurs principally upon entry into the axon [31]. We found
that both NF-H and NF-M were signi¢cantly hyperphos-
phorylated at SMI31 and SMI33 epitopes in AD brain. It is
believed that the abnormal phosphorylation of the microtu-
bule-associated protein tau in AD brain is due to an imbal-
anced regulation of protein kinases and protein phosphatases.
The reduced activities of the tau protein phosphatases PP-2A
and PP-1 in AD brain [16,17] would induce increased phos-
phorylation of tau either by diminished dephosphorylation of
this protein directly or by tau kinases that are activated by
phosphorylation, such as ERK and CaMKII (see [32]). That
there might indeed be a general activation of kinases by phos-
phorylation in the AD brain is indicated by their immunohis-
tochemical association in activated forms with the neuro¢bril-
lary tangles in the AD hippocampus (see [32]). NF are a
component of the cytoskeleton and are located in the same
cellular compartment as microtubules and tau and, like tau,
would also be exposed to the abnormal regulation of phos-
phorylation in AD. In vitro studies have shown that NF sub-
units can be further phosphorylated over and above their
normal phosphorylation by various protein kinases [3,33^
35]. In situ such hyperphosphorylation might then lead to
disassembly of NF [36] as was shown in vitro by phosphory-
lation with protein kinase A [37].
In addition to hyperphosphorylation, we also found that
the levels of all three NF subunits were signi¢cantly increased
in AD brain. A previous study reported a similar ¢nding but
based on investigation of only two AD and two control cases
[38]. To date no indications for increased synthesis of the
NFPs but rather, in the case of NF-M and NF-L, a decrease
in its message in AD have been found [39]. It is, therefore,
more likely that the NFPs accumulate in AD because the
access of the catabolic enzymes to these proteins is inhibited
by their abnormal hyperphosphorylation as has been shown
in vitro [40]. Similar mechanisms have been implied for the
abnormally hyperphosphorylated tau in AD [13,41]. Whether
the accumulation of hyperphosphorylated NFPs might lead to
their association with the neuro¢brillary tangles in AD brain
is not clear yet, although it is somewhat indicated by the
immunohistochemical staining (see Fig. 1). However, these
experiments are not fully conclusive since it cannot be ex-
cluded that the antibodies, although not reactive with tau
on Western blots, might still be reactive with tau polymerized
into PHF in tissue due to conformational changes.
Since SH-SY5Y, a human neuroblastoma cell line, only
contains negligible amounts of phosphorylated tau proteins
that did not cross-react with the phosphorylation-dependent
NF antibodies at the concentrations employed here, we used
this cell line as a model for the study of NFPs. To explore the
mechanism of NF phosphorylation and elevation in AD
brain, we treated the SY5Y cells with OA, a potent inhibitor
of PP-2A and PP-1. A dose-dependent hyperphosphorylation
and accumulation of NFPs in the cell body were observed
after inhibition of phosphatases. It has been shown previously
that phosphorylation regulates the intracellular transport of
NFPs from cytoplasm to the processes [42]. According to the
data obtained from the present study, we speculate that in AD
the de¢ciency in PP-2A/PP-1 activities induces hyperphos-
phorylation of NFPs which thereafter leads to an accumula-
tion of these proteins in the cytoplasm. The e¡ect of accumu-
lated hyperphosphorylated NFPs on the biology of the
neuron is as yet not understood. A recent report has raised
the possibility that NFPs might chaperone the assembly of tau
into ¢laments [43].
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